P/E ratio for GlycoMimetics (GLYC)
P/E ratio as of April 2024 (TTM): -3.32
According to GlycoMimetics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.32308. At the end of 2022 the company had a P/E ratio of -3.44.
P/E ratio history for GlycoMimetics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.44 | 194.11% |
| 2021 | -1.17 | -65.44% |
| 2020 | -3.39 | -13.55% |
| 2019 | -3.92 | -51.17% |
| 2018 | -8.03 | -45.03% |
| 2017 | -14.6 | 261.41% |
| 2016 | -4.04 | -52.68% |
| 2015 | -8.54 | -26.48% |
| 2014 | -11.6 | 910.63% |
| 2013 | -1.15 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -411.37% | 🇺🇸 USA |
 Pfizer PFE | 13.7 | -510.78% | 🇺🇸 USA |
 Sanofi SNY | 14.3 | -529.50% | 🇫🇷 France |
 Palatin Technologies PTN | -0.6385 | -80.79% | 🇺🇸 USA |
 bluebird bio
BLUE | -0.9343 | -71.88% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.